Samsung Biologics Receives the Terra Carta Seal
The company was awarded the Terra Carta Seal in recognition of its commitment to creating a sustainable future.
Samsung Biologics announced on Jan. 11, 2023 that it has been awarded the Sustainable Markets Initiative’s Terra Carta Seal. The Seal was launched at COP26 by His Majesty King Charles III when he was Prince of Wales, and it recognizes global companies that are driving innovation and demonstrating their commitment to creating genuinely sustainable markets. It is being awarded to companies whose ambitions are aligned with those of the Terra carta, a recovery plan for Nature, People, and Planet, launched in January 2021.
Samsung is one of the 19 companies to have been awarded the 2022 Terra Carta Seal. The company affirmed its commitment to achieving net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier as part of its global response to climate change.
“We are honored to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort,” said John Rim, CEO and president of Samsung Biologics, in a company press release. “Healthcare is at a pivotal moment and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”
Source: Samsung Biologics
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
